Zheng Quan Shi Bao Wang·2025-05-30 09:51Core Insights - The biovaccine sector saw a rise of 1.01%, ranking 10th among concept sectors, with 33 stocks increasing in value, including Wanbangde, which hit the daily limit, and notable gains from Guanhao Bio, Kexing Pharmaceutical, and Kanghua Bio, which rose by 8.88%, 7.40%, and 6.06% respectively [1][2] - The sector experienced a net inflow of 137 million yuan from main funds, with 31 stocks receiving net inflows, and five stocks exceeding 30 million yuan in net inflows, led by Fosun Pharma with 54.52 million yuan [2][3] Sector Performance - The top-performing sectors included pork (2.39%), chicken farming (1.94%), and innovative drugs (1.56%), while sectors like controllable nuclear fusion (-3.47%) and humanoid robots (-2.90%) faced declines [2] - The biovaccine sector's performance was supported by significant net inflows, with Wanbangde leading with a net inflow rate of 41.21%, followed by Haiwang Bio and Jindike [3] Stock Highlights - Key stocks in the biovaccine sector included: - Fosun Pharma: 5.23% increase, 54.52 million yuan net inflow, 2.82% turnover rate [3] - Taige Pharmaceutical: 3.60% increase, 44.07 million yuan net inflow, 3.92% turnover rate [3] - Wanbangde: 10.02% increase, 42.69 million yuan net inflow, 3.12% turnover rate [3] - Haiwang Bio: 3.57% increase, 34.73 million yuan net inflow, 5.19% turnover rate [3] - Guanhao Bio: 8.88% increase, 21.12 million yuan net inflow, 17.97% turnover rate [3]